Wikipedia -WSS

Wikipedia

author：focus 2025-09-28 23:24:33 - browse：268

Stock exchange — Drew Angerer/Getty Images

Structure Therapeutics reported Monday that its oral GLP-1 drug led to weight loss in two small studies, leading shares to surge in pre-market trading.

In a 12-week Phase 2a study, the daily pill in a capsule formulation led to 6.2% placebo-adjusted weight loss. In a separate 12-week pharmacokinetics study, the company tested a new tablet formulation of the drug, called GSBR-1290, and it led to placebo-adjusted weight loss of up to 6.9%.

Though it’s difficult to compare across different studies, the results appear to approach the levels of weight loss seen at 12 weeks in a separate Phase 2 study of Eli Lilly’s GLP-1 pill called orforglipron. That entire study lasted 36 weeks, but at 12 weeks, participants had about 6%-7% placebo-adjusted weight loss.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Food makers tried to stack nutrition panel with preferred experts

leisure time

WSS

Will the IRA bring competition to the biologics market?

FDA panel endorses Alnylam’s heart drug — after picking it apart

IRA could hurt research into orphan drugs for rare diseases

Food makers tried to stack nutrition panel with preferred experts

How housing is health care on Long Island

PEPFAR is under serious threat — and so is global health

leisure time

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Walmart eyes Medicare Advantage provider ChenMed

Medicare proposal to cover medical devices draws a mixed reaction

How medical schools plan to diversify without affirmative action

United colonoscopy coverage change 'may cost lives,' doctors say

Pig kidney works a record two months in donated body

In Memoriam: Notable people who died in 2023

A common UTI test for kids haunts adults as a traumatic 'nightmare'

Alkermes shareholders re

Diverse clinical trials: Why aren’t we there yet?

explore

FDA proposes changes to key medical devices approval pathway

Acelyrin, a rare IPO success, stumbles in its first big test

Acelyrin, a rare IPO success, stumbles in its first big test

How medical schools plan to diversify without affirmative action

Private equity could exacerbate cardiology's overuse problem, experts fear

Generate Biomedicines machine learning biotech raises $273M

focus

knowledge

leisure time

focus